CDT - Cdt Equity Inc

NYSE * Health Care * Biotechnology

$4.08

$-1.81 (-30.73%)

About Cdt Equity Inc

CDT Equity Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.

CDT Key Statistics

Market Cap

$19.27M

0

P/B Ratio

4.50

EPS

$-397.65

Employees

6

How CDT Compares to Peers

CDT is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

#6

of 6

CompanyP/EGrowthCompare
CDTN/A0%-
AMGN24.50%vs AMGN
GILD20.60%vs GILD
VRTX28.80%vs VRTX
REGN18.20%vs REGN
BIIB20.0-0%vs BIIB

Cdt Equity Inc Company Information

Headquarters
California; U.S.A
Website
www.conduitpharma.com
Sector
Health Care
Industry
Biotechnology
Data Updated:
Ready to invest in CDT?

Commission-free trading available. Affiliate links.

Upcoming Events for CDT